Politico July 1, 2024
By Chelsea Cirruzzo and Ben Leonard

Driving the Day

HOW CHEVRON COULD SLOW THE FDA — A Friday Supreme Court ruling could mean it will take longer to develop new drugs and medical devices, former FDA attorneys say.

The Supreme Court overturned a Reagan-era precedent, called the Chevron deference, which required judges to defer to federal agencies’ interpretations of ambiguous federal laws.

The White House said the rule takes the country “backwards” and could “thwart efforts to respond to a global pandemic.”

The ruling could also mean new court challenges for the Biden administration’s Medicare drug negotiation policy and more pressure on Congress and the federal courts to hone their knowledge of health policy.

Slowed response time: The former FDA attorneys worry that the FDA’s process...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Halozyme Pulls €2B Acquisition Bid as Evotec Commits to Standalone Strategy
More than half of US adults could benefit from GLP-1 medications, researchers find
RNA editing is the next frontier in gene therapy—here's what you need to know
Rand roadblock: Biotech bill’s uncertain future
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry

Share This Article